Accretion Pharmaceuticals Ltd
Incorporated in 2012, Accretion Pharmaceuticals Limited is a pharmaceutical company that manufactures and sells tablets, capsules, and other healthcare products.[1]
- Market Cap ₹ 72.3 Cr.
- Current Price ₹ 65.0
- High / Low ₹ 83.0 / 53.8
- Stock P/E 7.96
- Book Value ₹ 41.9
- Dividend Yield 0.00 %
- ROCE 46.4 %
- ROE 65.4 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
- Debtor days have improved from 116 to 74.2 days.
- Company's working capital requirements have reduced from 127 days to 65.3 days
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Half Yearly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|
| 13.35 | 57.38 | 82.55 | |
| 10.78 | 45.49 | 67.94 | |
| Operating Profit | 2.57 | 11.89 | 14.61 |
| OPM % | 19.25% | 20.72% | 17.70% |
| 0.05 | 0.09 | 0.19 | |
| Interest | 0.40 | 1.44 | 1.11 |
| Depreciation | 0.22 | 0.77 | 0.81 |
| Profit before tax | 2.00 | 9.77 | 12.88 |
| Tax % | 25.00% | 30.40% | |
| 1.49 | 6.79 | 9.08 | |
| EPS in Rs | 3.72 | 8.31 | 9.57 |
| Dividend Payout % | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 159% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 130% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | 65% |
Balance Sheet
Figures in Rs. Crores
| Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|
| Equity Capital | 4.00 | 8.17 | 11.12 |
| Reserves | 1.49 | 7.12 | 35.46 |
| 13.48 | 14.10 | 7.85 | |
| 8.47 | 10.48 | 4.64 | |
| Total Liabilities | 27.44 | 39.87 | 59.07 |
| 5.25 | 6.09 | 8.67 | |
| CWIP | 0.00 | 0.00 | 0.00 |
| Investments | 0.00 | 0.00 | 0.00 |
| 22.19 | 33.78 | 50.40 | |
| Total Assets | 27.44 | 39.87 | 59.07 |
Cash Flows
Figures in Rs. Crores
| Mar 2024 | Mar 2025 | |
|---|---|---|
| -11.51 | 5.75 | |
| -5.48 | -1.61 | |
| 17.08 | -4.18 | |
| Net Cash Flow | 0.09 | -0.04 |
Ratios
Figures in Rs. Crores
| Mar 2024 | Mar 2025 | |
|---|---|---|
| Debtor Days | 158.58 | 74.17 |
| Inventory Days | 564.06 | 188.49 |
| Days Payable | 256.32 | 69.41 |
| Cash Conversion Cycle | 466.31 | 193.25 |
| Working Capital Days | 189.47 | 65.33 |
| ROCE % | 46.36% |
Documents
Announcements
-
Investor Presentation
17 November 2025 - Investors/Analysts presentation on unaudited results for half year ended 30 September 2025.
-
Press Release
17 November 2025 - H1 FY26 revenue Rs43.74cr (+135.6% YoY), EBITDA Rs7.07cr, PAT Rs4.75cr.
-
Outcome of Board Meeting
14 November 2025 - Board approved H1 FY26 unaudited results: revenue Rs 4,373.62L, PAT Rs 475.22L; limited review dated 14 Nov 2025.
-
Analysts/Institutional Investor Meet/Con. Call Updates
13 November 2025 - Earnings conference call on 18 Nov 2025 at 11:00 IST to discuss H1 FY26 results; management to attend.
-
General Updates
28 October 2025 - SEBI show-cause notice dated 28 October 2025 alleges forward-looking projections at investor meet before IPO.
Concalls
-
Nov 2025TranscriptNotesPPT
Business Profile[1]
The company manufactures pharmaceutical formulations, including both generic and branded products. It offers contract and third-party manufacturing services for domestic and international markets. Its clientele includes private institutions, government sectors (state and central), and reputed pharmaceutical companies.